The day pharma’s weight-loss gold rush intensified
Published on: Oct. 31, 2025, 11 a.m. | Source: Livemint
Lilly’s quarterly results Thursday, combined with Novo Nordisk’s unsolicited offer for a startup, confirm the $72 billion anti-obesity market is among pharma’s hottest.
